Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Vomiting 3Nausea 3Lymphoma 2Delirium 2Sarcoma, Alveolar Soft Part 1Recurrence 1Pain 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Trastuzumab 625Paclitaxel 576Cyclophosphamide 555Docetaxel 484Capecitabine 401Letrozole 376Fulvestrant 326Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 184Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 138Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Lorazepam × Clear all
NCT01067144 2022-05-05

Stanford Accelerated Recovery Trial (START)

Stanford University

Phase 3 Terminated
422 enrolled 12 charts
BreastThoracic

Breast Neoplasms, Lung Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡